2014 guidelines of taiwan society of cardiology (TSOC) for the management of pulmonary arterial hypertension

Chih Hsin Hsu, Wan Jing Ho, Wei Chun Huang, Yu Wei Chiu, Tsu Shiu Hsu, Ping Hung Kuo, Hsao Hsun Hsu, Jia Kan Chang, Chin Chang Cheng, Chao Lun Lai, Kae Woei Liang, Shoa Lin Lin, Shih Hsien Sung, Wei Chuan Tsai, Ken Pen Weng, Kai Sheng Hsieh, Wei Hsian Yin, Shing Jong Lin, Kuo Yang Wang

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Pulmonary hypertension (PH) is a hemodynamic and pathophysiologic condition, defined as a mean pulmonary arterial pressure exceeding 25 mmHg at rest. According to the recent classifications, it is grouped into pulmonary arterial hypertension (PAH), heart-related, lung-related, thromboembolic, and miscellaneous PH. In the past two decades, tremendous advances have occurred in the field of PH. These include (1) development of clinical diagnostic algorithm and a monitoring strategy dedicated to PAH, (2) defining strong rationales for screening at-risk populations, (3) advent of pulmonary specific drugs which makes PAH manageable, (4) recognition of needs of having proper strategy of combining existing pulmonary specific drugs, and/or potential novel drugs, (5) pursuit of clinical trials with optimal surrogate endpoints and study durations, (6) recognition of critical roles of PH/right ventricular function, as well as interdependence of ventricles in different conditions, especially those with various phenotypes of heart failure, and (7) for rare diseases, putting equal importance on carefully designed observation studies, various registries, etc., besides double blind randomized studies. In addition, ongoing basic and clinical research has led to further understanding of relevant physiology, pathophysiology, epidemiology and genetics of PH/PAH. This guidelines from the working group of Pulmonary Hypertension of the Taiwan Society of Cardiology is to provide updated guidelines based on the most recent international guidelines as well as Taiwan's domestic research on PH. The guidelines aremainly for themanagement of PAH (Group 1); however themajority of content can be helpful for managing other types of PH.

Original languageEnglish
Pages (from-to)401-444
Number of pages44
JournalActa Cardiologica Sinica
Volume30
Issue number5
Publication statusPublished - 2014 Sep 1

Fingerprint

Cardiology
Taiwan
Pulmonary Hypertension
Guidelines
Lung
Pharmaceutical Preparations
Right Ventricular Function
Molecular Epidemiology
Rare Diseases
Research
Double-Blind Method
Registries
Arterial Pressure
Heart Failure
Biomarkers
Hemodynamics
Observation
Clinical Trials
Phenotype

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Hsu, C. H., Ho, W. J., Huang, W. C., Chiu, Y. W., Hsu, T. S., Kuo, P. H., ... Wang, K. Y. (2014). 2014 guidelines of taiwan society of cardiology (TSOC) for the management of pulmonary arterial hypertension. Acta Cardiologica Sinica, 30(5), 401-444.
Hsu, Chih Hsin ; Ho, Wan Jing ; Huang, Wei Chun ; Chiu, Yu Wei ; Hsu, Tsu Shiu ; Kuo, Ping Hung ; Hsu, Hsao Hsun ; Chang, Jia Kan ; Cheng, Chin Chang ; Lai, Chao Lun ; Liang, Kae Woei ; Lin, Shoa Lin ; Sung, Shih Hsien ; Tsai, Wei Chuan ; Weng, Ken Pen ; Hsieh, Kai Sheng ; Yin, Wei Hsian ; Lin, Shing Jong ; Wang, Kuo Yang. / 2014 guidelines of taiwan society of cardiology (TSOC) for the management of pulmonary arterial hypertension. In: Acta Cardiologica Sinica. 2014 ; Vol. 30, No. 5. pp. 401-444.
@article{e07a1fb17f3d41e29b3896de4fb072e7,
title = "2014 guidelines of taiwan society of cardiology (TSOC) for the management of pulmonary arterial hypertension",
abstract = "Pulmonary hypertension (PH) is a hemodynamic and pathophysiologic condition, defined as a mean pulmonary arterial pressure exceeding 25 mmHg at rest. According to the recent classifications, it is grouped into pulmonary arterial hypertension (PAH), heart-related, lung-related, thromboembolic, and miscellaneous PH. In the past two decades, tremendous advances have occurred in the field of PH. These include (1) development of clinical diagnostic algorithm and a monitoring strategy dedicated to PAH, (2) defining strong rationales for screening at-risk populations, (3) advent of pulmonary specific drugs which makes PAH manageable, (4) recognition of needs of having proper strategy of combining existing pulmonary specific drugs, and/or potential novel drugs, (5) pursuit of clinical trials with optimal surrogate endpoints and study durations, (6) recognition of critical roles of PH/right ventricular function, as well as interdependence of ventricles in different conditions, especially those with various phenotypes of heart failure, and (7) for rare diseases, putting equal importance on carefully designed observation studies, various registries, etc., besides double blind randomized studies. In addition, ongoing basic and clinical research has led to further understanding of relevant physiology, pathophysiology, epidemiology and genetics of PH/PAH. This guidelines from the working group of Pulmonary Hypertension of the Taiwan Society of Cardiology is to provide updated guidelines based on the most recent international guidelines as well as Taiwan's domestic research on PH. The guidelines aremainly for themanagement of PAH (Group 1); however themajority of content can be helpful for managing other types of PH.",
author = "Hsu, {Chih Hsin} and Ho, {Wan Jing} and Huang, {Wei Chun} and Chiu, {Yu Wei} and Hsu, {Tsu Shiu} and Kuo, {Ping Hung} and Hsu, {Hsao Hsun} and Chang, {Jia Kan} and Cheng, {Chin Chang} and Lai, {Chao Lun} and Liang, {Kae Woei} and Lin, {Shoa Lin} and Sung, {Shih Hsien} and Tsai, {Wei Chuan} and Weng, {Ken Pen} and Hsieh, {Kai Sheng} and Yin, {Wei Hsian} and Lin, {Shing Jong} and Wang, {Kuo Yang}",
year = "2014",
month = "9",
day = "1",
language = "English",
volume = "30",
pages = "401--444",
journal = "Acta Cardiologica Sinica",
issn = "1011-6842",
publisher = "Republic of China Society of Cardiology",
number = "5",

}

Hsu, CH, Ho, WJ, Huang, WC, Chiu, YW, Hsu, TS, Kuo, PH, Hsu, HH, Chang, JK, Cheng, CC, Lai, CL, Liang, KW, Lin, SL, Sung, SH, Tsai, WC, Weng, KP, Hsieh, KS, Yin, WH, Lin, SJ & Wang, KY 2014, '2014 guidelines of taiwan society of cardiology (TSOC) for the management of pulmonary arterial hypertension', Acta Cardiologica Sinica, vol. 30, no. 5, pp. 401-444.

2014 guidelines of taiwan society of cardiology (TSOC) for the management of pulmonary arterial hypertension. / Hsu, Chih Hsin; Ho, Wan Jing; Huang, Wei Chun; Chiu, Yu Wei; Hsu, Tsu Shiu; Kuo, Ping Hung; Hsu, Hsao Hsun; Chang, Jia Kan; Cheng, Chin Chang; Lai, Chao Lun; Liang, Kae Woei; Lin, Shoa Lin; Sung, Shih Hsien; Tsai, Wei Chuan; Weng, Ken Pen; Hsieh, Kai Sheng; Yin, Wei Hsian; Lin, Shing Jong; Wang, Kuo Yang.

In: Acta Cardiologica Sinica, Vol. 30, No. 5, 01.09.2014, p. 401-444.

Research output: Contribution to journalReview article

TY - JOUR

T1 - 2014 guidelines of taiwan society of cardiology (TSOC) for the management of pulmonary arterial hypertension

AU - Hsu, Chih Hsin

AU - Ho, Wan Jing

AU - Huang, Wei Chun

AU - Chiu, Yu Wei

AU - Hsu, Tsu Shiu

AU - Kuo, Ping Hung

AU - Hsu, Hsao Hsun

AU - Chang, Jia Kan

AU - Cheng, Chin Chang

AU - Lai, Chao Lun

AU - Liang, Kae Woei

AU - Lin, Shoa Lin

AU - Sung, Shih Hsien

AU - Tsai, Wei Chuan

AU - Weng, Ken Pen

AU - Hsieh, Kai Sheng

AU - Yin, Wei Hsian

AU - Lin, Shing Jong

AU - Wang, Kuo Yang

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Pulmonary hypertension (PH) is a hemodynamic and pathophysiologic condition, defined as a mean pulmonary arterial pressure exceeding 25 mmHg at rest. According to the recent classifications, it is grouped into pulmonary arterial hypertension (PAH), heart-related, lung-related, thromboembolic, and miscellaneous PH. In the past two decades, tremendous advances have occurred in the field of PH. These include (1) development of clinical diagnostic algorithm and a monitoring strategy dedicated to PAH, (2) defining strong rationales for screening at-risk populations, (3) advent of pulmonary specific drugs which makes PAH manageable, (4) recognition of needs of having proper strategy of combining existing pulmonary specific drugs, and/or potential novel drugs, (5) pursuit of clinical trials with optimal surrogate endpoints and study durations, (6) recognition of critical roles of PH/right ventricular function, as well as interdependence of ventricles in different conditions, especially those with various phenotypes of heart failure, and (7) for rare diseases, putting equal importance on carefully designed observation studies, various registries, etc., besides double blind randomized studies. In addition, ongoing basic and clinical research has led to further understanding of relevant physiology, pathophysiology, epidemiology and genetics of PH/PAH. This guidelines from the working group of Pulmonary Hypertension of the Taiwan Society of Cardiology is to provide updated guidelines based on the most recent international guidelines as well as Taiwan's domestic research on PH. The guidelines aremainly for themanagement of PAH (Group 1); however themajority of content can be helpful for managing other types of PH.

AB - Pulmonary hypertension (PH) is a hemodynamic and pathophysiologic condition, defined as a mean pulmonary arterial pressure exceeding 25 mmHg at rest. According to the recent classifications, it is grouped into pulmonary arterial hypertension (PAH), heart-related, lung-related, thromboembolic, and miscellaneous PH. In the past two decades, tremendous advances have occurred in the field of PH. These include (1) development of clinical diagnostic algorithm and a monitoring strategy dedicated to PAH, (2) defining strong rationales for screening at-risk populations, (3) advent of pulmonary specific drugs which makes PAH manageable, (4) recognition of needs of having proper strategy of combining existing pulmonary specific drugs, and/or potential novel drugs, (5) pursuit of clinical trials with optimal surrogate endpoints and study durations, (6) recognition of critical roles of PH/right ventricular function, as well as interdependence of ventricles in different conditions, especially those with various phenotypes of heart failure, and (7) for rare diseases, putting equal importance on carefully designed observation studies, various registries, etc., besides double blind randomized studies. In addition, ongoing basic and clinical research has led to further understanding of relevant physiology, pathophysiology, epidemiology and genetics of PH/PAH. This guidelines from the working group of Pulmonary Hypertension of the Taiwan Society of Cardiology is to provide updated guidelines based on the most recent international guidelines as well as Taiwan's domestic research on PH. The guidelines aremainly for themanagement of PAH (Group 1); however themajority of content can be helpful for managing other types of PH.

UR - http://www.scopus.com/inward/record.url?scp=84907258441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907258441&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:84907258441

VL - 30

SP - 401

EP - 444

JO - Acta Cardiologica Sinica

JF - Acta Cardiologica Sinica

SN - 1011-6842

IS - 5

ER -